Sleep-related experimental peptide · Fact sheet
DSIP
Also known as Delta sleep-inducing peptide · Emideltide
DSIP is an experimental peptide named for early sleep research. Small human studies do not establish it as an effective insomnia treatment; one controlled study found weak objective effects and no subjective sleep improvement.
What is DSIP?
Delta sleep-inducing peptide is also called emideltide. Its name describes a research history, not a proven clinical result.
Benefits people look for
Deeper sleep, fewer awakenings, and improved next-day recovery are common expectations. The distinction between a subjective experience and measured sleep improvement matters here.
What the evidence supports
- Some early reports suggested sleep effects, but later controlled findings were weak and inconsistent.
- The 16-person study did not show improved subjective sleep quality.
All research areas
- Insomnia
- Sleep efficiency
- Sleep physiology
Anecdotal reports & lived experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens.
Deeper-feeling sleep, with inconsistent or fading effects
Comments in one discussion include descriptions of deeper sleep, feeling more rested without longer sleep, and a follow-up saying the initial benefit had faded.
These are different people with uncontrolled sleep problems and other exposures. No sleep-laboratory measurements verify deeper sleep, and the thread cannot establish tolerance or durability.
Read the DSIP discussion ↗Side effects & risks
- FDA describes peptide-quality concerns and inadequate safety information for proposed routes.
- Small historical studies cannot establish the likelihood of uncommon harms or effects of prolonged exposure.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research: how strong is it?
Limited or unclear evidenceThe historical human literature is small. A double-blind study of 16 people with chronic insomnia did not find a major therapeutic benefit; some apparent changes could reflect differences in the placebo group.
Selected research to read
Small matched-pairs double-blind study; weak objective effects and no subjective improvement.
Historical report with limited detail in the indexed record.
FDA approval & research status
DSIP is not an FDA-approved insomnia medicine. The cited older studies should not be presented as an active late-stage development program.
No FDA-approved use is documented in the records summarized on this page.
Historical studies; no FDA-approved sleep use
DSIP is not an FDA-approved insomnia medicine. The cited older studies should not be presented as an active late-stage development program.
This summarizes the cited product or research record. Trial phases do not establish successful completion of earlier stages, and a stopped program is not ongoing development. Approval applies only to the labeled product, use and population.
What we still don’t know
- Reproducible benefit for chronic insomnia
- Effects on next-day function
- Long-term safety and medication interactions
The takeaway
The name DSIP is more confident than the clinical evidence: dependable sleep benefit remains unproven.
Sources & further reading
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- 1fdaFDA: safety concerns for selected bulk substances
Ingredient-specific safety findings; compounding review is not drug approval.
- 2pubmedDSIP in chronic insomnia: a controlled study
Small matched-pairs double-blind study; weak objective effects and no subjective improvement.
- 3